インスリン分泌促進薬　SU薬とグリニド

出版社： フジメディカル出版
著者：
発行日： 2006-04-20
分野： 臨床医学：内科  >  糖尿病
ISBN： 4939048667
電子書籍版： 2006-04-20 （初版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,080 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

商品紹介

近年、膵β細胞におけるSU薬の作用の分子機構が明らかにされるに至り、同じインスリン分泌促進薬でも作用様式や持続時間の差が生じる理由が科学的に検証されている。このような背景から、インスリン分泌促進薬の発売から半世紀が経過した今、その特性をまとめ直すことが必要となった。

目次

  • インスリン分泌促進薬　SU薬とグリニド

    ―目次―

    序
    1．インスリン分泌促進薬の歴史と現状
    2．インスリン分泌促進薬の作用機序：血糖降下作用
    3．膵β細胞以外への作用
    4．インスリン分泌促進薬の大規模臨床試験
    5．インスリン分泌促進薬の二次無効
    6．インスリン分泌促進薬を第一選択薬とする場合
    7．インスリン分泌促進薬とα-グルコシダーゼ阻害薬との併用：
    　　　メリットと注意点
    8．インスリン分泌促進薬とメトホルミンとの併用：
    　　　メリットと注意点
    9．インスリン分泌促進薬とチアゾリジン系薬剤との併用：
    　　　メリットと注意点
    10．インスリン分泌促進薬からインスリンへの切り替え
    11．インスリン分泌促進薬とインスリンの併用
    12．インスリンからインスリン分泌促進薬への切り替え
    13．高齢者におけるインスリン分泌促進薬の使いかた
    14．腎障害を伴った症例におけるインスリン分泌促進薬の使いかた
    15．肥満を伴った症例におけるインスリン分泌促進薬の使いかた
    16．遺伝子異常を伴った症例(MODY3)における
    　　　インスリン分泌促進薬の使いかた
    17．インスリン分泌促進薬の使用に際しての注意点：
    　　　低血糖、体重増加
    18．インスリン分泌促進薬の禁忌および慎重投与例
    19．インスリン分泌促進薬の服薬指導

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. インスリン分泌促進薬の歴史と現状

P.12 掲載の参考文献
1) Janbon M et al:Accidents hypoglycemiques graves par un sulfamidothiodiazol(le VK 57 ou 2254 RP). Montpellier Med 441:21-22, 1942
 
2) Zimmerman BR:Sulfonylureas. Endocrinol Metab Clin North Am 26 (3):511-522, 1997
PubMed
3) Feinglos MN et al:Treatment of type 2 diabetes mellitus. Med Clin North Am 82:757-791, 1988
 
4) University Group Diabetes Program:A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes:Mortality results. Diabetes 19:785-830, 1970
 
5) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study(UKPDS)Group. Lancet 352:837-853, 1998
 
6) Garratt KN et al:Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33(1):119-124, 1999
PubMed
7) The DECODE study group, Glucose tolerance and mortality:comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354:617-621, 1999
 
8) Tominaga M et al:lmpaired glucose tolerance is a risk factor for cardiovascular diseases, but not impaired fasting glucose. Diabetes Care 22 (6):920-924, 1999
 
9) Plosker GL et al:Repaglinide:a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 22 (6):389-411, 2004
PubMed

2. インスリン分泌促進薬の作用機序:血糖降下作用

P.17 掲載の参考文献
1) Seino S:ATP-sensitive potassium channels:A model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 61:337-362, 1999
 
2) Detimary P et al:Concentration dependence and time course of the effects of glucose on adenine and guanine nucleotides in mouse pancreatic islets. J Biol Chem 271 (34):20559, 1996
PubMed
3) Inagaki N et al:Reconstitution of I KATP:An inward rectifier subunit plus the sulfonylurea receptor. Science 270:1166-1170, 1995
PubMed
4) Miki T et al:Roles of KATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol 38 (6):917-925, 2005
PubMed
5) Ashfield R et al:Identification of the high-affinity tolbutamide site on the SURI subunit of the K(ATP)channel. Diabetes 48 (6):1341-1347, 1999
 
6) Mikhailov MV et al:Molecular structure of the glibenclamide binding site of the beta-cell K(ATP)channel. FEBS Lett 499 (1-2):154-160, 2001
 
7) Nagashima K et al:Sulfonylurea and non-sulfonylurea hypoglycemic agents:pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 66:S75-78, 2004
PubMed

3. 膵β細胞以外への作用

P.21 掲載の参考文献
1) Seino S et al:Physiological and pathophysiological roles of ATP-sensitive K+channels. Prog Biophys Mol Biol 81:133-176, 2003
PubMed
2) Nagashima K et al:Sulfonylurea and non-sulfonylurea hypoglycemic agents:pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 66 Suppl 1:S75-78, 2004
PubMed
3) Sunaga Y et al:The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+channels and insulin secretion:comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 431:119-125, 2001
PubMed
4) Chachin M et al:Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP)channels. J Pharmacol Exp Ther 304:1025-1032, 2003
PubMed
5) Miki T et al:Roles of K ATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol 38:917-925, 2005
PubMed
6) Yamada M et al:Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel. J physiol 499:715-720, 1997
 
7) Miki T et al:Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med 8:466-472, 2002
PubMed
P.25 掲載の参考文献
1) 加来浩平:新規スルホニルウレア剤グリメピリドの肝糖産生及びケトン体産生に及ぼす影響. 新薬と臨床 49:147-151, 2000
 
2) Fukuen S et al:Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptorγ Agonistic Activity. J Biol Chem 280:23653-23659, 2005
 
3) Tsunekawa T et al:Plasma adiponectin plays an important role in improving resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 26:285-289, 2003
PubMed
4) Muller G et al:Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol- specific phospholipase C in rat adipocytes. Biochem Pharmacol 69:761-780, 2005
PubMed
5) Kumar N et al:Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J Exp Biol 205:3739-3746, 2002
PubMed
6) 森豊ほか:遅延過剰型インスリン分泌に対するナテグリニドの効果OLETFラットを用いた検討. Progress in Medicine 20:2515-2518, 2000
 
7) 熊倉淳ほか:ナテグリニドの肝糖取り込み作用とインスリン分泌の関係. 糖尿病 48 (Suppl 2):S265, 2005
 
P.31 掲載の参考文献
1) Takahara N et al:Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia 40:662-670, 1997
PubMed
2) Sheetz MJ et al:Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588, 2002
PubMed
3) Akanuma Y et al:Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Res Clin Pract 5:81-90, 1988
PubMed
4) Marquie G:Preventive effect of gliclazide on experimental atherosclerosis in rabbits. Diabetologia 14:269-275, 1978
PubMed
5) Jennings PE et al:Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients:clinical assessment. Metabolism 41 (Suppl 1):36-39, 1992
 
6) O'Brien RC et al:In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 14:201-206, 2000
 
7) Scott NA et al:Gliclazide:a general free radical scavenger. Eur J Pharmacol 208:175-177, 1991
PubMed
8) Noda Y et al:Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals:an ESR study. Res Commun Mol Pathol Pharmacol 96:115-124, 1997
PubMed
9) Lu M et al:Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219-1224, 1998
PubMed
10) Mamputu JC et al:Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diabetes Complications 16:284-293, 2002
PubMed
11) Assaloni R et al:Effects of S21403(mitiglinide)on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48:1919-1924, 2005
PubMed
12) Cai H et al:Endothelial dysfunction in cardiovascular diseases:the role of oxidant stress. Circ Res 87:840-844, 2000
PubMed
13) Vallejo S et al:Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment. J Diabetes Complications 14:224-233, 2000
PubMed
14) Fava D et al:Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med 19:752-757, 2002
 
15) Manzella D et al:Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 28:366-371, 2005
PubMed
16) 赤藤修司ほか:新規スルホニルウレア剤グリメピリド(HOE490, Amaril(R))の抗粥状動脈硬化作用. 糖尿病合併症 15 (Supple1):68, 2001
 
17) Schiekofer S et al:Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. Diabetes Obes Metab 5:251-261, 2003
PubMed
18) Sobol AB et al:The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 50:1-16, 2000
PubMed
19) Davi G et al:Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769-1774, 1990
PubMed
20) Tschoepe D et al:Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20:166-170, 1990
PubMed
21) Schaeffer G et al:Alterations in platelet Ca2+signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia 42:167-176, 1999
PubMed
22) Ziboh VA et al:Increased biosynthesis of thromboxane A2 by diabetic platelets. Eur J Clin Invest 9:223-228, 1979
PubMed
23) Qi R et al:Sulphonylurea agents inhibit platelet aggregation and[Ca2+]i elevation induced by arachidonic acid. Biochem Pharmacol 49:1735-1739, 1995
 
24) Siluk D et al:Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 45:1034-1037, 2002
PubMed
P.37 掲載の参考文献
1) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). UK Prospective Diabetes Study(UKPDS)Group. Lancet 352:854-865, 1998
PubMed
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study(UKPDS)Group. Lancet 352:837-853, 1998
 
3) O'Brien RC et al:In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 14:201-206, 2000
 
4) Omi H et al:Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells:effect of antidiabetic medicines. J Diabetes Complications 16:201-208, 2002
PubMed
5) Katakami N et al:Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima- media thickness in subjects with type 2 diabetes. Diabetologia 47:1906-1913, 2004
 
6) Shakuto S et al:Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 182:209-217, 2005
PubMed
7) 多田久也:Pulse wave velocity(PWV)に及ぼすグリメピリドの効果. 糖尿病 47:465-468, 2004
 
8) Langenfeld MR et al:Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients with Type 2 Diabetes Mellitus. Circulation 111:2525-2531, 2005
PubMed
9) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
10) Yamasaki Y et al:alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 67:204-210, 2005
PubMed
11) Esposito K et al:Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus. Circulation 110:214-219, 2004
PubMed

4. インスリン分泌促進薬の大規模臨床試験

P.47 掲載の参考文献
1) Mori Y et al:Suppression of body weight gain preserves acute insulin response to glucose in the portal vein of spontaneously type 2 diabetic rats with visceral obesity. Endocrine 26:139-146, 2005
PubMed
2) Mori Y et al:Role of early insulin secretion in post-glucose loading hyperglycemia and post-fat loading hyperlipidemia:Comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab 6:422-431, 2004
 
3) Mori Y et al:Clinical characteristics of nateglinide response as assessed by insulinogenic indices:Preliminary study to determined optimal indication for nateglinide. Adv Ther 20:352-359, 2003
 
4) Mori Y et al:Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading:results of glucose loading on 2 consecutive days. Diabetes Obes Metab 7:182-188, 2005
PubMed
5) Mori Y et al:Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 23:39-43, 2004
PubMed
6) Mori Y et al:Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes Assessment by meal tolerance test. Endocrine 25:203-206, 2004
PubMed
7) Uchino H et al:Impairment of early insulin responses after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes:assessment using nateglinide, a new insulin secretagogue. Endocr J 47:639-641, 2000
 
8) Shimabukuro M et al:A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in type 2 diabetic patients. Diabet Med 21:983-986, 2004
PubMed
9) Assaloni R et al:Effects of S21403(mitiglinide)on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48:1919-1924, 2005
PubMed
10) Esposito K et al:Regression of carotid atherosclerosis bu control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004
 
11) McMurray JJ et al:ESC Congress 2004
 
12) Schernthaner G et al:GUIDE Study:Double-blinde comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34:535-542, 2004
 

5. インスリン分泌促進薬の二次無効

P.52 掲載の参考文献
1) U. K. Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352 (9131):837-853, 1998
PubMed
2) 鈴木春彦ほか:I糖尿病の悪化要因としての糖毒性 膵β細胞疲弊の分子機構:膵β細胞糖毒性. Diabetes Frontier 15 (2):146-150, 2004
Medical*Online
3) Rustenbeck I:Desensitization of insulin secretion. Biochem Pharmacol 63 (11):1921-1935, 2002
PubMed
4) Satoh J et al:Secondary sulfonylurea failure:comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 70(3):291-297, 2005
PubMed
5) Maedler K et al:Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110(6):851-860, 2002
PubMed
6) 麻生好正ほか:軽症2型糖尿病におけるナテグリニドの3年間の長期投与による至適例の検討. Prog Med 23 (9):2409-2415, 2003
Medical*Online
7) 玉澤直樹ほか:2型糖尿病の治療における速効・短時間型インスリン分泌促進薬ナテグリニドの適応症例の検討. 臨床と研究 80 (11):150-156, 2003
 
8) 寺田 央:2型糖尿病に対するナテグリニドの長期投与における二次無効および安全性についての検討. 臨床と研究 82 (2):179-184, 2005
 
9) Rotella CM et al:Glucagon-like peptide 1(GLP-1)and metabolic diseases. J Endocrinol Invest 28 (8):746-758, 2005
PubMed
10) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366(9493):1279-1289, 2005
PubMed

6. インスリン分泌促進薬を第一選択薬とする場合

P.56 掲載の参考文献
1) 日本糖尿病学会編:糖尿病治療ガイド2006-2007, 第1版, 文光堂, 東京, 2006
 
2) 日本糖尿病学会:経口血糖降下薬による治療. 科学的根拠に基づく糖尿病診療ガイドライン(日本糖尿病学会 編), 第1版, 南江堂, 東京, 2004, pp37-46
 
3) 岩本安彦:糖尿病の診療-オーバービュー. 糖尿病診療の実際-症例から学ぶ治療最前線(岩本安彦監修), 第1版, メジカルビュー社, 東京, 2006, pp8-17
 

7. インスリン分泌促進薬とα-グルコシダーゼ阻害薬との併用 : メリットと注意点

P.60 掲載の参考文献
1) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
2) The DECODE study group, European Diabetes Epidemiology Group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology:Collaborative analysis of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
 
3) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
PubMed
4) Chiasson JL et al:The STOP-NIDDM Trial:an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance:rationale, design, and preliminary screening data. Study to Prevent Non-lnsulin-Dependent Diabetes Mellitus. Diabetes Care 21:1720- 1725, 1998
 
5) Holman RR et al:A Randomized Double-Blind Trial of Acarbose in Type 2 Diabetes Shows Improved Glycemic Control Over 3 Years(U. K. Prospective Diabetes Study 44). Diabetes Care 22:960-964, 1999
 
6) 飯嶋敏彦ほか:インスリン非依存型糖尿病患者に対するα-グルコシダーゼ阻害薬(ボグリボース)とスルフォニル尿素剤(SU剤)との併用療法-特にSU剤の減量効果の検討-. 薬理と治療 25:841-849, 1997
 
7) 河盛隆造ほか:糖質水解酵素阻害剤の追加療法がSU剤治療NIDDMの血糖管理に与える影響. 糖尿病 39:527-529, 1996
 
8) 垂井清一郎ほか:α-グルコシダーゼ阻害剤投与中のインスリン非依存糖尿病患者に対するAY4166併用投与による臨床的有用性の検討. 薬理と臨床 7:767-784, 1997
Medical*Online

8. インスリン分泌促進薬とメトホルミンとの併用:メリットと注意点

P.66 掲載の参考文献
1) Zhou G et al:Role of AMP-activated protein kinase in mechanism of metformin action. JCI 108:1167-1174, 2001
PubMed
2) DeFronzo RA et al:Efficacy of metformin in patient with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
PubMed
3) Cook MN et al:Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28:995-1000, 2005
PubMed
4) Nagasaka S et al:Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med 21:136-141, 2004
PubMed
5) Hanefeld M et al:One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147, 2004
PubMed
6) 小坂樹得ほか:AY4166投与によるインスリン非依存糖尿病患者の食後血糖推移および薬物体内動態の検討. 薬理と臨牀 7:653-668, 1997
 
7) Mori Y et al:Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 23:39-43, 2004
PubMed
8) Mori Y et al:Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia:comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab 6:422-431, 2004
PubMed
9) Sato Y et al:Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl-]D-phenylalanine(A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12:53-59, 1991
PubMed
10) Karara AH et al:The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 39:172-179, 1999
PubMed
11) Mari A et al:Beta-cell function in mild type 2 diabetic patients:effects of 6-month glucose lowering with nateglinide. Diabetes Care 28:1132-1138, 2005
PubMed
12) 小坂樹得ほか:速効・短時間型血糖降下剤AY4166のインスリン非依存糖尿病に対する長期投与試験. 薬理と臨牀 7:669-697, 1997
 
13) Horton ES et al:Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
PubMed
14) Marre M et al:Nateglinide improves glycaemic control when added to metformin monotherapy:results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 4:177-186, 2002
PubMed
15) Gerich J et al:PRESERVE-β:Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093, 2005
 

9. インスリン分泌促進薬とチアゾリジン系薬剤との併用 : メリットと注意点

P.70 掲載の参考文献
1) Okuno A et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
PubMed
2) Neuschwander-Tetri BA et al:Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38:1008-1017, 2003
 
3) Maeda N et al:PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
 
4) Ricote M et al:Expression of the peroxisome proliferators-activated receptorγ(PPARγ)in human athrosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614-7619, 1998
 
5) Pasceri V et al:Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferators-activated receptor-γ activators. Circulation 101:235-238, 2000
 
6) Rosenstock J et al:Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 25:1529-1533, 2002
 
7) Kerenyi Z et al:Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 63:213-223, 2004
PubMed
8) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
PubMed
9) Finegood DT et al:βcell mass dynamics in Zucker diabetic fatty rats;Rosigritazone prevents the rise in net cell death. Diabetes 50:1021-1029, 2001
 

10. インスリン分泌促進薬からインスリンへの切り替え

P.75 掲載の参考文献
1) インスリン療法マニュアル第3版(小林正編), 文光堂, 2005
 
2) 糖尿病治療ガイド2004-2005(日本糖尿病学会編), 文光堂, 2004
 
3) 科学的根拠に基づく糖尿病診療ガイドライン(日本糖尿病学会編), 南江堂, 2004
 
4) 糖尿病専門医研修ガイドブック改訂第2版(日本糖尿病学会編), 診断と治療社, 2004
 
5) 糖尿病ナビゲーター(門脇孝編), メディカルレビュー社, 2002
 
6) 今日から始める外来インスリン療法(松澤佑次編), 医薬ジャーナル社, 1997
 

11. インスリン分泌促進薬とインスリンの併用

P.79 掲載の参考文献
1) Davis T et al:Insulin therapy in type 2 diabetes. Med Clin N Am 88:865-895, 2004
PubMed
2) 高橋健二ほか:2型糖尿病のどのような患者にインスリン治療が必要か-その臨床指標の分析. 内分泌・糖尿病科 20:626-632, 2005
 
3) 高橋健二ほか:インスリン非依存型糖尿病に対する眠前中間型インスリン療法の有用性. 糖尿病 41:995-1001, 1998
 
4) Yki-Jarvinen H:The liver as a target for therapy in NIDDM. 糖尿病 38(suppl 1):100-101, 1995
 
5) Riddle MC et al:Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 21:1052-1057, 1998
PubMed
6) Kawamori R et al:Fasting plus prandial insulin supplements improved insulin secretory ability in NIDDM patients. Diabetes Care 12:680-685, 1989
 
7) Landstedt-Hallin L et al:Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 18:1183-1186, 1995
PubMed
8) Yki-Jarvinen H et al:Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
PubMed
9) Shank ML et al:Bedtime insulin/daytime glipizide:effective therapy for sulfonylurea failure in NIDDM. Diabetes 44:165-172, 1995
PubMed
10) Riddle MC et al:The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086, 2003
 

12. インスリンからインスリン分泌促進薬への切り替え

P.83 掲載の参考文献
1) 河盛隆造:インスリン療法-強化インスリン療法とは. 診断と治療 84:1665-1671, 1996
Medical*Online
2) 河盛隆造:なぜ中間型インスリンが使われるのだろう. プラクティス 15:236-239, 1998
 
3) 弘世貴久:外来インスリン導入の強い味方, 超速効型インスリン. なぜ, 今外来インスリン導入なのか. プラクティス 22:393-397, 2005
 
4) 弘世貴久ほか:超速効型インスリンを用いた2型糖尿病患者の外来インスリン導入の試み. プラクティス 21:85-90, 2004
Medical*Online
5) 鈴木一永:インスリンをいつやめるのか? インスリンの離脱について. なぜ, 今外来インスリン導入なのか. プラクティス 22:421-424, 2005
 
6) UK Prospective Diabetes Study(UKPDS)Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 352:837-853, 1998
 
7) The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
 
8) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata study. Diabetes Care 22:920-924, 1999
 
9) Lepore M et al:Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
PubMed
10) Heinemann L et al:Time-action profiles of the long-acting insulin analogue glargine(HOE901)in comparison with those of NPH insulin and placebo. Diabetes Care 23:644-649, 2000
 
11) Yoshihara T et al:Therapeutic efficacy of mitiglinide administration combined with once daily insulin glargine switching from multiple daily insulin regimen using insulin aspart and glargine. Endocr J 53:67-72, 2006
PubMed
12) Hirose T and Kawamori R:Diabetes in Japan. Curr Diabetes Report 5:226-229, 2005
 
13) Igarashi Y et al:Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding changes in body weight. Endocr J 52:683-689, 2005
PubMed
14) Uchino H et al:Impairment of early insulin response after glucose load rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabtes:assessment using nateglinide, a new insulin secretagogue. Endocr J 47:639-641, 2000
 
15) Hirose T et al:The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects:rapid insulin stimulation by nateglinide in IGT subjects. Endocr J 49:649-652, 2002
PubMed

13. 高齢者におけるインスリン分泌促進薬の使い方

P.87 掲載の参考文献
1) 大庭建三:加齢と糖尿病, 老年医療のあゆみと展望(日本老年医学会編), メジカルビュー社, 東京, 2003, pp157-159
 
2) 井藤英喜:高齢者糖尿病の診断と治療. 日老医誌 39:257-260, 2002
 
3) 大庭建三ほか:老年糖尿病患者の管理. 日本糖尿病学会編, 診断と治療社, 東京, 2004, pp110-113
 
4) 大庭建三:老年者糖尿病の経口血糖降下療法. 日老医誌 38:288-290, 2001
 
5) 佐倉宏:SU薬と速効型インスリン分泌促進薬. 内分泌・糖尿病科 20 (Suppl. 2):254-260, 2005
 
6) 大庭建三ほか:スルホニル尿素薬療法中の老年者糖尿病の血糖管理-朝食前血糖値測定の臨床的意義. 日老医誌 36:122-127, 1999
 
7) Van Staa T et al:Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50:735-741, 1997
PubMed
8) Schemthaner G et al:GUIDE Study:Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34:535-542, 2004
 

14. 腎障害を伴った症例におけるインスリン分泌促進薬の使い方

P.91 掲載の参考文献
1) Jonsson A et al:Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53:429-435, 1998
PubMed
2) Rosenkranz B et al:Pharmacokinetics and safety of glimepiride at clinically effective dose in diabetic patients with renal impairment. Diabetologia 39:1617-1624, 1996
PubMed
3) Rydberg T et al:Hypoglycemic activity of glyburide(glibenclamide)metabolites in humans. Diabetes Care 17:1026-1030, 1994
PubMed
4) Devineni D et al:Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 43:163- 170, 2003
 
5) Nagai T et al:Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diab Res Clin Prac 59:191-194, 2003
 
6) Defronzo RA et al:Is glucose intolerance harmful for the uremic patient? Kidney lnt 28(Suppl 17):S88-97, 1985
 

15. 肥満を伴った症例におけるインスリン分泌促進薬の使い方

P.96 掲載の参考文献
1) UK Prospective Diabetes Study(UKPDS)Group:Effect of intensive blood-glucose control with metoformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352:854-865, 1998
 
2) UK Prospective Diabetes Study(UKPDS)Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853, 1998
 
3) Kumar N et al:Gliclazide increases insulin receptor tyrosine phosphorylaiton but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J Exp Biol 205:3739-3746, 2002
 
4) Fukuzawa M et al:Inhibition of tumor necrosis factor-α with anti-diabetic agents. Diabetes Res Clin Pract 43:147-154, 1999
 
5) 森豊:経口薬と抗酸化作用. 臨床医 31:358-363, 2005
 
6) 山田宜和ほか:SU薬アマリール(グリメピリド)-肥満への影響を中心として-. BIO Clinica 18:63-67, 2003
 
7) 高山秀一:グリメピリドの膵外作用-抗動脈硬化作用を中心に-. BIO Clinica 19:58-63, 2004
 
8) Lebovits HE:Management of hyperglycemia with oral atihyperglycemic agents in type 2 diabetes. Joslin's Diabetes Mellitus, Kahn CR et al, 14th edition, USA, Lippincott Williams and Wilkins, 2005, pp687-709
 
9) Luger A et al:Sulfonylharnstoff Therapie ohne Gewichtszunahme. JATROS Diabetes & Stoffwechsel 2:1-7, 1999
 
10) The DECODE study goup et al:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology:Collaborative analysis of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
 
11) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
 
12) Horton ES et al:Nateglinide alone and in combination with metoformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
 

16. 遺伝子異常を伴った症例 (MODY3) におけるインスリン分泌促進薬の使い方

P.100 掲載の参考文献
1) Fajans SS et al:Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 345:971-980, 2003
 
2) Tonooka N et al:High frequencies of mutations in the HNF-1α gene in non-obese patients with diabetes of youth in Japanese and identification of a case of digenic inheritance. Diabetologia 45:1709-1712, 2002
 
3) Yamada S et al:Identification of mutations in the hepatocyte nuclear factor-1α(MODY3)gene in Japanese subjects with IDDM. Diabetes 46:1643-1647, 1997
 
4) Dukes ID et al:Defective pancreatic β-cell glycolytic signaling in hepatocyte nuclear factor-1α-deficient mice. J Biol Chem 273:24457-24464, 1998
 
5) Hansen T et al:Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene:evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes 46:726-730, 1997
 
6) Pearson ER et al:Genetic cause of hyperglycemia and response to treatment in diabetes. Lancet 362:1275-1281, 2003
PubMed
7) Sagen JV et al:Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1α mutation carriers. Diabet Med 22:406-409, 2005
 
8) Boileau P et al:Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1α-deficient mice. A mechanism for hypersensitivity to sulphonylurea therapy in patients with maturity-onset diabetes of the young, type 3(MODY3). Diabetes 51(Suppl 3):S343-S348, 2002
 

17. インスリン分泌促進薬の使用に際しての注意点:低血糖, 体重増加

P.104 掲載の参考文献
1) Holstein A et al:Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Res Metab Rev 17:467-473, 2001
PubMed
2) Schemthaner G et al:GUIDE study:double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34:535-542, 2004
 
3) Miwa S et al:Efficacy and safety of once daily gliclazide(20mg/day)compared with nateglinide. Endocrine Journal 51:393-398, 2004
 
4) Hollander PA et al:Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988, 2001
PubMed
5) Gerich J et al:PRESERVE-β. Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093-2099, 2005
 
6) Fukuen S et al:Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280:23653-23659, 2005
PubMed
7) 小林正ほか:2型糖尿病患者に対するグリメピリド1日1回投与による臨床効果. 糖尿病 47:727-735, 2005
 
8) Cathelineau G et al:Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting:Effect of 2 years of gliclazide treatment-The Diadem Study. Metabolism 12(Suppl 1):31-34, 1997
 
9) Horton ES et al:Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
PubMed
10) 福田元ほか:ナテグリニド投与における糖尿病患者の体重変化. Prog Med 21:2255-2258, 2001
Medical*Online
11) Hirose T et al:The effect of nateglinide following oral glucose load in impaired glucose tolerance subjects:rapid insulin stimulation by nateglinide in IGT subjects. Endocrine Journal 49:649-652, 2002
PubMed

18. インスリン分泌促進薬の禁忌および慎重投与例

P.109 掲載の参考文献
1) 平田幸正:第8章 経口血糖降下薬. 糖尿病の治療, 第2版, 東京, 文光堂, 2003, pp497-550
 
2) 草間真紀子ほか:経口糖尿病用薬の特徴と薬物療法における位置づけ. 経口糖尿病用薬の特徴と処方上の注意点 (伊賀立二監修), 第1版, メディカルレビュー社, 大阪, 2001, pp17-38
 
3) Kobayashi T et al:Insulin intervention to preserve beta cells in slowly progressive insulin dependent(type1) diabetes mellitus. Ann NY Acad Sci 958:117-130, 2002
 
4) Jacobson GF et al:Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 193 (1):118-124, 2005
 
5) Langer O et al:A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 343 (16):1134-1138, 2000
PubMed
6) Daaboul JJ et al:The management of type 2 diabetes in children and adolescents. Minerva Pediatr 56 (3):255-264, 2004.
PubMed
7) Chelliah A et al:Hypoglycaemia in elderly patients with diabetes mellitus:caouses and strategies for prevention. Drug Aging 21 (8):511-530, 2004
PubMed
8) Ashcroft FM et al:KATP channels and insulin secretion:their role in health and disease. Diabetologia 42:903-919, 1999
 

19. インスリン分泌促進薬の服薬指導

P.117 掲載の参考文献
1) 小川晶三ほか:スルホニル尿素薬. 糖尿病療養指導のためのコア・カリキュラム(三村悟郎ほか監訳), 改訂第3版, メディカルレビュー社, 大阪, 2002, p304
 
2) Herings RMC et al:Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345 (8959):1195-1198, 1995
 
3) Taniguchi A et al:Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 50 (4):477-480, 2001
PubMed
4) 原田浩史ほか:スルホニル尿素薬のヒト血清蛋白結合に及ぼすフィブラート系薬の影響. 臨床と薬物治療 23 (4):126-128, 2004
 

書評

最近チェックした商品履歴

Loading...